Recent News

• 12.11.2025 - Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
• 12.08.2025 - Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
• 12.04.2025 - VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
• 11.25.2025 - VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
• 11.13.2025 - VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
• 11.10.2025 - VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

Recent Filings

• 12.11.2025 - 8-K Current report
• 11.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 8-K Current report
• 11.13.2025 - 8-K/A Current report
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.10.2025 - 8-K/A Current report
• 11.07.2025 - 8-K Current report
• 11.04.2025 - 4 Statement of changes in beneficial ownership of securities